8605 Effective Strategies For Pregnancy And Lactation-Associated Osteoporosis: Teriparatide Use In Focus
Bibliographic record
Abstract
Abstract Disclosure: D.S. Ali: None. A.A. Khan: Advisory Board Member; Self; Amgen Inc, Alexion, Ascendis. Grant Recipient; Self; Takeda, Amolyt, Calcilytix. Speaker; Self; Amgen Inc, Alexion. M. Brandi: Consulting Fee; Self; Aboca, Alexion, Amolyt, Bruno Farmaceutici, Calcilytix, Echolight, Kyowa Kirin, Personal Genomics, UCB. Speaker; Self; Abiogen, Alexion, Amolyt, Amorphical, Bruno Farmaceutici, CoGeDi, Echolight, Amgen Inc, Eli Lilly & Company. Background: Pregnancy and lactation-associated osteoporosis (PLO) is a rare but debilitating condition characterized by fragility fractures occurring during late pregnancy or during lactation, primarily affecting the spine. Current treatment strategies lack clear guidance on optimal management due to the absence of clinical trials. Previous treatment strategies focused on conventional measures such as the use of calcium supplements, vitamin D, back braces, and weaning from breastfeeding. Antiresorptive therapies have also been used. The use of teriparatide (TPD) in PLO has gained more attention in the past decade due to its anabolic properties and potential suitability for women of childbearing age. Methods: We searched PubMed, Google Scholar, and Medline until August 2023. Over 300 cases with PLO have been published. We included cases with a confirmed diagnosis of PLO based on clinical history and radiographic confirmation. Cases with prior fragility fractures, traumatic fractures or prior diagnosis of osteoporosis have been excluded. Results: We identified a total of 175 cases of PLO treated with either TPD alone or TPD followed by antiresorptive therapy. We also identified another cohort of 81 women where separation of those receiving TPD from other treatment was not possible. Most women in our analysis were primiparas (85.7%). The duration of TPD use ranged from 4 to 24 months. Despite the acknowledged risk of recurrent fractures in PLO, 82.8% of those treated with TPD did not sustain new fractures during a follow-up period ranging from 4 months to 9 years. Although direct treatment comparative studies are lacking, available evidence suggests that TPD treatment significantly improves bone mineral density (BMD) at the spine (33% at 24 months) and hip (18.6% at 18-24 months). Bisphosphonates, demonstrate varying degrees of BMD improvement. Bone turnover markers such as C-telopeptide cross-linked type I collagen (CTx) and osteocalcin have been studied in patients with PLO, suggesting that they may be predictive of BMD response to TPD treatment. Conclusion: This review highlights the severity of PLO and its health consequences, advocates for increased awareness and timely interventions. TPD emerges as a promising therapeutic option, offering substantial BMD responses and potentially serving as the primary choice for PLO treatment, given its safety profile and short half-life. Especially with consideration of the potential long-term effects associated with bisphosphonate use in women of childbearing age. Use of BTMs need further validation. Presentation: 6/3/2024
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame distilled prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.
Codex and Gemma teacher scores by category
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.000 | 0.000 |
| Meta-epidemiology (narrow) | 0.000 | 0.000 |
| Meta-epidemiology (broad) | 0.000 | 0.000 |
| Bibliometrics | 0.000 | 0.000 |
| Science and technology studies | 0.000 | 0.000 |
| Scholarly communication | 0.000 | 0.000 |
| Open science | 0.000 | 0.000 |
| Research integrity | 0.000 | 0.001 |
| Insufficient payload (model declined to judge) | 0.000 | 0.000 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one teacher head, not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".